Clinical Trials Using Fluorine F 18 L-glutamate Derivative BAY94-9392

Clinical trials are research studies that involve people. The clinical trials on this list are studying Fluorine F 18 L-glutamate Derivative BAY94-9392. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-5 of 5
  • 11C-Glutamine and 18F-FSPG PET Imaging in Diagnosing Patients with Metastatic Colorectal Cancer

    The clinical trial studies how well 11C-glutamine and 18F-FSPG positron emission tomography (PET) imaging works in detecting tumors in patients with metastatic colorectal cancer compared to standard imaging methods such as magnetic resonance imaging (MRI) or computed tomography (CT) scanning.
    Location: Vanderbilt University / Ingram Cancer Center, Nashville, Tennessee

  • 18F-FSPG PET / CT in Finding Lesions in Patients with Advanced or Metastatic Cancer Receiving Therapy

    This phase II trial studies how well fluorine F 18 L-glutamate derivative BAY94-9392 (18F-FSPG) positron emission tomography / computed tomography (PET / CT) imaging works in finding an area of abnormal tissue (lesion) both before and after the start of therapy in patients with cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or has spread to other places in the body (metastatic). Diagnostic procedures, such as 18F-FSPG PET / CT, may help find and diagnose lesions caused by cancer and monitor a patient's response to treatment.
    Location: Stanford Cancer Institute Palo Alto, Palo Alto, California

  • 18F-FSPG PET in Imaging Patients with Liver Cancer before Undergoing Surgery or Transplant

    This clinical trial studies fluorine F 18 L-glutamate derivative BAY94-9392 (18F-FSPG) positron emission tomography (PET) in imaging patients with liver cancer before undergoing surgery or transplant. Diagnostic procedures, such as 18F-FSPG PET, may help find and diagnose liver cancer and find out how far the disease has spread.
    Location: Vanderbilt University / Ingram Cancer Center, Nashville, Tennessee

  • PET Imaging with 18F-FSPG in Detecting Tumors in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

    This clinical trial studies how well positron emission tomography (PET) with fluorine F 18 L-glutamate derivative BAY94-9392 (18F-FSPG) works in detecting tumors in patients with advanced epithelial ovarian, fallopian tube, or peritoneal cancer. PET imaging using 18F-FSPG may identify tumors when they are smaller and more responsive to various treatment(s).
    Location: Vanderbilt University / Ingram Cancer Center, Nashville, Tennessee

  • 18F-FSPG PET / CT in Imaging Patients with Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules

    This phase II trial compares fluorine F 18 L-glutamate derivative BAY94-9392 (18F-FSPG) positron emission tomography (PET) / computed tomography (CT) to the standard of care fludeoxyglucose F-18 (18F-FDG) PET / CT in imaging patients with newly diagnosed lung cancer or indeterminate pulmonary nodules. PET / CT uses a radioactive glutamate (one of the common building blocks of protein) called 18F-FSPG which may be able to recognize differences between tumor and healthy tissue. Since tumor cells are growing, they need to make protein, and other building blocks, for cell growth that are made from glutamate and other molecules. PET / CT using a radioactive glutamate may be a more effective method of diagnosing lung cancer than the standard PET / CT using a radioactive glucose (sugar), such as 18F-FDG.
    Location: Vanderbilt University / Ingram Cancer Center, Nashville, Tennessee